Ricki Lewis | Oct 1, 2001 | 8 min read
As the AIDS pandemic enters its third decade, viral resistance is beginning to counter the success of "highly active antiretroviral treatment" (HAART), the multidrug cocktails introduced in 1996. "Viral resistance is a significant problem, particularly for patients who began therapy in the pre-protease inhibitor era and who developed resistance to multiple reverse transcriptase inhibitors," says Robert Schooley, a professor of infectious diseases at the University of Colorado Health Sciences Cen